How to buy Tandem Diabetes Care stock - 05 March

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Tandem Diabetes Care stock

Own Tandem Diabetes Care stock in just a few minutes.


Fact checked

Tandem Diabetes Care, Inc is a medical devices business based in the US. Tandem Diabetes Care shares (TNDM) are listed on the NASDAQ and all prices are listed in US Dollars. Tandem Diabetes Care employs 1,500 staff and has a trailing 12-month revenue of around USD$498.8 million.

How to buy shares in Tandem Diabetes Care

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Tandem Diabetes Care. Find the stock by name or ticker symbol: TNDM. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Tandem Diabetes Care reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Tandem Diabetes Care, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Tandem Diabetes Care. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Tandem Diabetes Care share price

Use our graph to track the performance of TNDM stocks over time.

Tandem Diabetes Care shares at a glance

Information last updated 2021-03-03.
52-week rangeUSD$43.69 - USD$123.74
50-day moving average USD$96.5542
200-day moving average USD$102.4473
Wall St. target priceUSD$127.67
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.96

Buy Tandem Diabetes Care shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stocks, Options, ETFs
Get two free stock valued between $2.50 and $250
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Stocks, Options, Cryptocurrency
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
Get 100 shares of stock (worth $1 to $6 a share)
Open and fund a new cash or margin account with $2,000+
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Interactive Brokers
Stocks, Bonds, Options
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Tandem Diabetes Care stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Tandem Diabetes Care under- or over-valued?

Valuing Tandem Diabetes Care stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Tandem Diabetes Care's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Tandem Diabetes Care's EBITDA

Tandem Diabetes Care's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$2.5 million.

The EBITDA is a measure of a Tandem Diabetes Care's overall financial performance and is widely used to measure a its profitability.

Tandem Diabetes Care financials

Revenue TTM USD$498.8 million
Gross profit TTM USD$260.5 million
Return on assets TTM -0.95%
Return on equity TTM -12.25%
Profit margin -6.89%
Book value $5.876
Market capitalisation USD$5.8 billion

TTM: trailing 12 months

Shorting Tandem Diabetes Care shares

There are currently 3.9 million Tandem Diabetes Care shares held short by investors – that's known as Tandem Diabetes Care's "short interest". This figure is 3.8% up from 3.7 million last month.

There are a few different ways that this level of interest in shorting Tandem Diabetes Care shares can be evaluated.

Tandem Diabetes Care's "short interest ratio" (SIR)

Tandem Diabetes Care's "short interest ratio" (SIR) is the quantity of Tandem Diabetes Care shares currently shorted divided by the average quantity of Tandem Diabetes Care shares traded daily (recently around 595971.14197531). Tandem Diabetes Care's SIR currently stands at 6.48. In other words for every 100,000 Tandem Diabetes Care shares traded daily on the market, roughly 6480 shares are currently held short.

However Tandem Diabetes Care's short interest can also be evaluated against the total number of Tandem Diabetes Care shares, or, against the total number of tradable Tandem Diabetes Care shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Tandem Diabetes Care's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Tandem Diabetes Care shares in existence, roughly 60 shares are currently held short) or 0.0711% of the tradable shares (for every 100,000 tradable Tandem Diabetes Care shares, roughly 71 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Tandem Diabetes Care.

Find out more about how you can short Tandem Diabetes Care stock.

Tandem Diabetes Care share dividends

We're not expecting Tandem Diabetes Care to pay a dividend over the next 12 months.

Have Tandem Diabetes Care's shares ever split?

Tandem Diabetes Care's shares were split on a 1:10 basis on 10 October 2017. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Tandem Diabetes Care shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Tandem Diabetes Care shares which in turn could have impacted Tandem Diabetes Care's share price.

Tandem Diabetes Care share price volatility

Over the last 12 months, Tandem Diabetes Care's shares have ranged in value from as little as $43.69 up to $123.74. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Tandem Diabetes Care's is 0.1601. This would suggest that Tandem Diabetes Care's shares are less volatile than average (for this exchange).

Tandem Diabetes Care overview

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin delivery system with Basal-IQ Technology; t:slim X2 with control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump and supported blood glucose meters for users, their caregivers, and their healthcare providers. Its products in development include t:sport insulin delivery system; and connected (mobile) health offerings. Further, the company offers Sugarmate, a mobile app for people with diabetes who use insulin. Tandem Diabetes Care, Inc. has a development and commercialization agreement with Dexcom, Inc. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was founded in 2006 and is headquartered in San Diego, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site